Brief: Hansa Biopharma Board Proposes That No Dividend Will Be Paid For 2025
11/02/2026 06:13
Feb 11 (Reuters) - Hansa Biopharma AB HNSA.ST: Q4 EBIT SEK -124.9 MILLION Q4 NET INCOME SEK -165 MILLION Q4 CASH & INVESTMENTS SEK 701.1 MILLION Q4 ADJUSTED EPS SEK -1.62 Q4 REVENUE SEK 76 MILLION THE BOARD PROPOSES THAT NO DIVIDEND WILL BE PAID FOR THE FINANCIAL YEAR 2025 Source text: ID:nWkr8PsNjh Further company coverage: HNSA.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS